|
|
|
|
|
SYDNEY, AU, May 12, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its CRO services to the US, is pleased to sponsor the Pre-ASCO China Summit 2022 event titled: Go/No Go Decisions Based on Early Phase Oncology Trials ('The Summit').
The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:
- Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
- Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China
Register here: https://www.eventbrite.com/e/pre-asco-china-2-gono-go-decisions-based-on-early-phase-oncology-trials-tickets-330427145487
Event Date:
- China Time: 9:00-10:30 AM, Saturday, May 14, 2022
- US EST Time: 9:00-10:30 PM, Friday, May 13, 2022
- US PST Time: 6:00-7:30 PM, Friday, May 13, 2022
Language: English, with Chinese simultaneous translation
Venue: Live Zoom Webinar
Moderator:
- Dr. Li Yan, CMO, Brii Biosciences; Managing Director, United States Chinese Anti-Cancer Association (USCACA)
The Summit will start with a presentation by Novotech's Senior Medical Monitor Dr. Ramandeep Sharma titled: Approaches, Experiences, and considerations for early phase go/no go.
A panel discussion will follow featuring leading clinical specialists including:
- Dr. Jin Li, Shanghai East Hospital
- Dr. Li Yan, CMO, Brii Biosciences; Managing Director, USCACA
- Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
- Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China
- Dr. Xiaoxia Yan, Highthink
- Dr. Jianmin Fang, Co-founder, CEO & CSO, RemeGen
- Dr. Joseph Eid, Chief Medical Officer, Hengrui
- Dr. Jon Wigginton, Senior Advisor and Chairman SAB, Cullinan Oncology; Former Head of Immuno-Oncology Early Clinical Development, BMS
Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.
Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.
NCGS was established in 1984 in South Carolina with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.
Novotech CEO Dr. John Moller said:
"This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs."
"Clients will receive seamless service, with a unified approach to systems and SOPs well developed," Moller said.
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.
With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.
Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.
Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.
About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. ("Novotech") is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact
Media Contact
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Novotech Health Holdings Pte Ltd |
| Feb 15, 2023 09:00 HKT/SGT |
|
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar |
| Feb 10, 2023 19:00 HKT/SGT |
|
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific |
| Feb 3, 2023 13:00 HKT/SGT |
|
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW |
| Jan 12, 2023 15:00 HKT/SGT |
|
Novotech Acquires European CRO, Strengthens Global Operations |
| Jan 12, 2023 15:00 HKT/SGT |
|
Novotech Acquires US-based Drug Development Consulting Firm, CBR International |
| Dec 20, 2022 11:00 HKT/SGT |
|
Novotech is Gold Sponsor at Biotech Showcase 2023 |
| Dec 15, 2022 10:00 HKT/SGT |
|
Data Shows 50% of New Trials Have Sites in Asia Pacific |
| Dec 6, 2022 11:00 HKT/SGT |
|
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials |
| Nov 11, 2022 17:00 HKT/SGT |
|
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy |
| Oct 25, 2022 18:00 HKT/SGT |
|
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper |
| More news >> |
 |
|
|
|
